0
     

Report Added
Report already added
Malignant Melanoma Drugs Market - Global Outlook and Forecast 2022-2028

Malignant Melanoma Drugs Market - Global Outlook and Forecast 2022-2028

This report contains market size and forecasts of Malignant Melanoma Drugs in Global, including the following market information:

Global Malignant Melanoma Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Malignant Melanoma Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
ImmunOthersapy Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Malignant Melanoma Drugs include Bristol-Myers Squibb, Enzon Pharmaceuticals, Exelixis, GlaxoSmithKline, Merck, Pfizer, Janssen Biotech, Hoffmann-La Roche Ltd and Navidea Biopharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Malignant Melanoma Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:
Global Malignant Melanoma Drugs Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Malignant Melanoma Drugs Market Segment Percentages, by Type, 2021 (%)
ImmunOthersapy
Targeted Therapy
Others
Global Malignant Melanoma Drugs Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Malignant Melanoma Drugs Market Segment Percentages, by Application, 2021 (%)
Hospitals
Clinics
Others
Global Malignant Melanoma Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Malignant Melanoma Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa

Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Malignant Melanoma Drugs revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Malignant Melanoma Drugs revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Bristol-Myers Squibb
Enzon Pharmaceuticals
Exelixis
GlaxoSmithKline
Merck
Pfizer
Janssen Biotech
Hoffmann-La Roche Ltd
Navidea Biopharmaceuticals
Novartis
Ono Pharmaceutical
Amgen
Table of Contents

1 Introduction to Research & Analysis Reports
1.1 Malignant Melanoma Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Malignant Melanoma Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Malignant Melanoma Drugs Overall Market Size
2.1 Global Malignant Melanoma Drugs Market Size: 2021 VS 2028
2.2 Global Malignant Melanoma Drugs Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Malignant Melanoma Drugs Players in Global Market
3.2 Top Global Malignant Melanoma Drugs Companies Ranked by Revenue
3.3 Global Malignant Melanoma Drugs Revenue by Companies
3.4 Top 3 and Top 5 Malignant Melanoma Drugs Companies in Global Market, by Revenue in 2021
3.5 Global Companies Malignant Melanoma Drugs Product Type
3.6 Tier 1, Tier 2 and Tier 3 Malignant Melanoma Drugs Players in Global Market
3.6.1 List of Global Tier 1 Malignant Melanoma Drugs Companies
3.6.2 List of Global Tier 2 and Tier 3 Malignant Melanoma Drugs Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Malignant Melanoma Drugs Market Size Markets, 2021 & 2028
4.1.2 ImmunOthersapy
4.1.3 Targeted Therapy
4.1.4 Others
4.2 By Type - Global Malignant Melanoma Drugs Revenue & Forecasts
4.2.1 By Type - Global Malignant Melanoma Drugs Revenue, 2017-2022
4.2.2 By Type - Global Malignant Melanoma Drugs Revenue, 2023-2028
4.2.3 By Type - Global Malignant Melanoma Drugs Revenue Market Share, 2017-2028
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Malignant Melanoma Drugs Market Size, 2021 & 2028
5.1.2 Hospitals
5.1.3 Clinics
5.1.4 Others
5.2 By Application - Global Malignant Melanoma Drugs Revenue & Forecasts
5.2.1 By Application - Global Malignant Melanoma Drugs Revenue, 2017-2022
5.2.2 By Application - Global Malignant Melanoma Drugs Revenue, 2023-2028
5.2.3 By Application - Global Malignant Melanoma Drugs Revenue Market Share, 2017-2028
6 Sights by Region
6.1 By Region - Global Malignant Melanoma Drugs Market Size, 2021 & 2028
6.2 By Region - Global Malignant Melanoma Drugs Revenue & Forecasts
6.2.1 By Region - Global Malignant Melanoma Drugs Revenue, 2017-2022
6.2.2 By Region - Global Malignant Melanoma Drugs Revenue, 2023-2028
6.2.3 By Region - Global Malignant Melanoma Drugs Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Malignant Melanoma Drugs Revenue, 2017-2028
6.3.2 US Malignant Melanoma Drugs Market Size, 2017-2028
6.3.3 Canada Malignant Melanoma Drugs Market Size, 2017-2028
6.3.4 Mexico Malignant Melanoma Drugs Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Malignant Melanoma Drugs Revenue, 2017-2028
6.4.2 Germany Malignant Melanoma Drugs Market Size, 2017-2028
6.4.3 France Malignant Melanoma Drugs Market Size, 2017-2028
6.4.4 U.K. Malignant Melanoma Drugs Market Size, 2017-2028
6.4.5 Italy Malignant Melanoma Drugs Market Size, 2017-2028
6.4.6 Russia Malignant Melanoma Drugs Market Size, 2017-2028
6.4.7 Nordic Countries Malignant Melanoma Drugs Market Size, 2017-2028
6.4.8 Benelux Malignant Melanoma Drugs Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Malignant Melanoma Drugs Revenue, 2017-2028
6.5.2 China Malignant Melanoma Drugs Market Size, 2017-2028
6.5.3 Japan Malignant Melanoma Drugs Market Size, 2017-2028
6.5.4 South Korea Malignant Melanoma Drugs Market Size, 2017-2028
6.5.5 Southeast Asia Malignant Melanoma Drugs Market Size, 2017-2028
6.5.6 India Malignant Melanoma Drugs Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Malignant Melanoma Drugs Revenue, 2017-2028
6.6.2 Brazil Malignant Melanoma Drugs Market Size, 2017-2028
6.6.3 Argentina Malignant Melanoma Drugs Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Malignant Melanoma Drugs Revenue, 2017-2028
6.7.2 Turkey Malignant Melanoma Drugs Market Size, 2017-2028
6.7.3 Israel Malignant Melanoma Drugs Market Size, 2017-2028
6.7.4 Saudi Arabia Malignant Melanoma Drugs Market Size, 2017-2028
6.7.5 UAE Malignant Melanoma Drugs Market Size, 2017-2028
7 Players Profiles
7.1 Bristol-Myers Squibb
7.1.1 Bristol-Myers Squibb Corporate Summary
7.1.2 Bristol-Myers Squibb Business Overview
7.1.3 Bristol-Myers Squibb Malignant Melanoma Drugs Major Product Offerings
7.1.4 Bristol-Myers Squibb Malignant Melanoma Drugs Revenue in Global Market (2017-2022)
7.1.5 Bristol-Myers Squibb Key News
7.2 Enzon Pharmaceuticals
7.2.1 Enzon Pharmaceuticals Corporate Summary
7.2.2 Enzon Pharmaceuticals Business Overview
7.2.3 Enzon Pharmaceuticals Malignant Melanoma Drugs Major Product Offerings
7.2.4 Enzon Pharmaceuticals Malignant Melanoma Drugs Revenue in Global Market (2017-2022)
7.2.5 Enzon Pharmaceuticals Key News
7.3 Exelixis
7.3.1 Exelixis Corporate Summary
7.3.2 Exelixis Business Overview
7.3.3 Exelixis Malignant Melanoma Drugs Major Product Offerings
7.3.4 Exelixis Malignant Melanoma Drugs Revenue in Global Market (2017-2022)
7.3.5 Exelixis Key News
7.4 GlaxoSmithKline
7.4.1 GlaxoSmithKline Corporate Summary
7.4.2 GlaxoSmithKline Business Overview
7.4.3 GlaxoSmithKline Malignant Melanoma Drugs Major Product Offerings
7.4.4 GlaxoSmithKline Malignant Melanoma Drugs Revenue in Global Market (2017-2022)
7.4.5 GlaxoSmithKline Key News
7.5 Merck
7.5.1 Merck Corporate Summary
7.5.2 Merck Business Overview
7.5.3 Merck Malignant Melanoma Drugs Major Product Offerings
7.5.4 Merck Malignant Melanoma Drugs Revenue in Global Market (2017-2022)
7.5.5 Merck Key News
7.6 Pfizer
7.6.1 Pfizer Corporate Summary
7.6.2 Pfizer Business Overview
7.6.3 Pfizer Malignant Melanoma Drugs Major Product Offerings
7.6.4 Pfizer Malignant Melanoma Drugs Revenue in Global Market (2017-2022)
7.6.5 Pfizer Key News
7.7 Janssen Biotech
7.7.1 Janssen Biotech Corporate Summary
7.7.2 Janssen Biotech Business Overview
7.7.3 Janssen Biotech Malignant Melanoma Drugs Major Product Offerings
7.7.4 Janssen Biotech Malignant Melanoma Drugs Revenue in Global Market (2017-2022)
7.7.5 Janssen Biotech Key News
7.8 Hoffmann-La Roche Ltd
7.8.1 Hoffmann-La Roche Ltd Corporate Summary
7.8.2 Hoffmann-La Roche Ltd Business Overview
7.8.3 Hoffmann-La Roche Ltd Malignant Melanoma Drugs Major Product Offerings
7.8.4 Hoffmann-La Roche Ltd Malignant Melanoma Drugs Revenue in Global Market (2017-2022)
7.8.5 Hoffmann-La Roche Ltd Key News
7.9 Navidea Biopharmaceuticals
7.9.1 Navidea Biopharmaceuticals Corporate Summary
7.9.2 Navidea Biopharmaceuticals Business Overview
7.9.3 Navidea Biopharmaceuticals Malignant Melanoma Drugs Major Product Offerings
7.9.4 Navidea Biopharmaceuticals Malignant Melanoma Drugs Revenue in Global Market (2017-2022)
7.9.5 Navidea Biopharmaceuticals Key News
7.10 Novartis
7.10.1 Novartis Corporate Summary
7.10.2 Novartis Business Overview
7.10.3 Novartis Malignant Melanoma Drugs Major Product Offerings
7.10.4 Novartis Malignant Melanoma Drugs Revenue in Global Market (2017-2022)
7.10.5 Novartis Key News
7.11 Ono Pharmaceutical
7.11.1 Ono Pharmaceutical Corporate Summary
7.11.2 Ono Pharmaceutical Business Overview
7.11.3 Ono Pharmaceutical Malignant Melanoma Drugs Major Product Offerings
7.11.4 Ono Pharmaceutical Malignant Melanoma Drugs Revenue in Global Market (2017-2022)
7.11.5 Ono Pharmaceutical Key News
7.12 Amgen
7.12.1 Amgen Corporate Summary
7.12.2 Amgen Business Overview
7.12.3 Amgen Malignant Melanoma Drugs Major Product Offerings
7.12.4 Amgen Malignant Melanoma Drugs Revenue in Global Market (2017-2022)
7.12.5 Amgen Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List of Tables
Table 1. Malignant Melanoma Drugs Market Opportunities & Trends in Global Market
Table 2. Malignant Melanoma Drugs Market Drivers in Global Market
Table 3. Malignant Melanoma Drugs Market Restraints in Global Market
Table 4. Key Players of Malignant Melanoma Drugs in Global Market
Table 5. Top Malignant Melanoma Drugs Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Malignant Melanoma Drugs Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Malignant Melanoma Drugs Revenue Share by Companies, 2017-2022
Table 8. Global Companies Malignant Melanoma Drugs Product Type
Table 9. List of Global Tier 1 Malignant Melanoma Drugs Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Malignant Melanoma Drugs Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Malignant Melanoma Drugs Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Malignant Melanoma Drugs Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Malignant Melanoma Drugs Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Malignant Melanoma Drugs Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Malignant Melanoma Drugs Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Malignant Melanoma Drugs Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Malignant Melanoma Drugs Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Malignant Melanoma Drugs Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Malignant Melanoma Drugs Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Malignant Melanoma Drugs Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Malignant Melanoma Drugs Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Malignant Melanoma Drugs Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Malignant Melanoma Drugs Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Malignant Melanoma Drugs Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Malignant Melanoma Drugs Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Malignant Melanoma Drugs Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Malignant Melanoma Drugs Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Malignant Melanoma Drugs Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Malignant Melanoma Drugs Revenue, (US$, Mn), 2023-2028
Table 30. Bristol-Myers Squibb Corporate Summary
Table 31. Bristol-Myers Squibb Malignant Melanoma Drugs Product Offerings
Table 32. Bristol-Myers Squibb Malignant Melanoma Drugs Revenue (US$, Mn), (2017-2022)
Table 33. Enzon Pharmaceuticals Corporate Summary
Table 34. Enzon Pharmaceuticals Malignant Melanoma Drugs Product Offerings
Table 35. Enzon Pharmaceuticals Malignant Melanoma Drugs Revenue (US$, Mn), (2017-2022)
Table 36. Exelixis Corporate Summary
Table 37. Exelixis Malignant Melanoma Drugs Product Offerings
Table 38. Exelixis Malignant Melanoma Drugs Revenue (US$, Mn), (2017-2022)
Table 39. GlaxoSmithKline Corporate Summary
Table 40. GlaxoSmithKline Malignant Melanoma Drugs Product Offerings
Table 41. GlaxoSmithKline Malignant Melanoma Drugs Revenue (US$, Mn), (2017-2022)
Table 42. Merck Corporate Summary
Table 43. Merck Malignant Melanoma Drugs Product Offerings
Table 44. Merck Malignant Melanoma Drugs Revenue (US$, Mn), (2017-2022)
Table 45. Pfizer Corporate Summary
Table 46. Pfizer Malignant Melanoma Drugs Product Offerings
Table 47. Pfizer Malignant Melanoma Drugs Revenue (US$, Mn), (2017-2022)
Table 48. Janssen Biotech Corporate Summary
Table 49. Janssen Biotech Malignant Melanoma Drugs Product Offerings
Table 50. Janssen Biotech Malignant Melanoma Drugs Revenue (US$, Mn), (2017-2022)
Table 51. Hoffmann-La Roche Ltd Corporate Summary
Table 52. Hoffmann-La Roche Ltd Malignant Melanoma Drugs Product Offerings
Table 53. Hoffmann-La Roche Ltd Malignant Melanoma Drugs Revenue (US$, Mn), (2017-2022)
Table 54. Navidea Biopharmaceuticals Corporate Summary
Table 55. Navidea Biopharmaceuticals Malignant Melanoma Drugs Product Offerings
Table 56. Navidea Biopharmaceuticals Malignant Melanoma Drugs Revenue (US$, Mn), (2017-2022)
Table 57. Novartis Corporate Summary
Table 58. Novartis Malignant Melanoma Drugs Product Offerings
Table 59. Novartis Malignant Melanoma Drugs Revenue (US$, Mn), (2017-2022)
Table 60. Ono Pharmaceutical Corporate Summary
Table 61. Ono Pharmaceutical Malignant Melanoma Drugs Product Offerings
Table 62. Ono Pharmaceutical Malignant Melanoma Drugs Revenue (US$, Mn), (2017-2022)
Table 63. Amgen Corporate Summary
Table 64. Amgen Malignant Melanoma Drugs Product Offerings
Table 65. Amgen Malignant Melanoma Drugs Revenue (US$, Mn), (2017-2022)

List of Figures
Figure 1. Malignant Melanoma Drugs Segment by Type in 2021
Figure 2. Malignant Melanoma Drugs Segment by Application in 2021
Figure 3. Global Malignant Melanoma Drugs Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Malignant Melanoma Drugs Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Malignant Melanoma Drugs Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Malignant Melanoma Drugs Revenue in 2021
Figure 8. By Type - Global Malignant Melanoma Drugs Revenue Market Share, 2017-2028
Figure 9. By Application - Global Malignant Melanoma Drugs Revenue Market Share, 2017-2028
Figure 10. By Region - Global Malignant Melanoma Drugs Revenue Market Share, 2017-2028
Figure 11. By Country - North America Malignant Melanoma Drugs Revenue Market Share, 2017-2028
Figure 12. US Malignant Melanoma Drugs Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Malignant Melanoma Drugs Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Malignant Melanoma Drugs Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Malignant Melanoma Drugs Revenue Market Share, 2017-2028
Figure 16. Germany Malignant Melanoma Drugs Revenue, (US$, Mn), 2017-2028
Figure 17. France Malignant Melanoma Drugs Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Malignant Melanoma Drugs Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Malignant Melanoma Drugs Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Malignant Melanoma Drugs Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Malignant Melanoma Drugs Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Malignant Melanoma Drugs Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Malignant Melanoma Drugs Revenue Market Share, 2017-2028
Figure 24. China Malignant Melanoma Drugs Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Malignant Melanoma Drugs Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Malignant Melanoma Drugs Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Malignant Melanoma Drugs Revenue, (US$, Mn), 2017-2028
Figure 28. India Malignant Melanoma Drugs Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Malignant Melanoma Drugs Revenue Market Share, 2017-2028
Figure 30. Brazil Malignant Melanoma Drugs Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Malignant Melanoma Drugs Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Malignant Melanoma Drugs Revenue Market Share, 2017-2028
Figure 33. Turkey Malignant Melanoma Drugs Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Malignant Melanoma Drugs Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Malignant Melanoma Drugs Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Malignant Melanoma Drugs Revenue, (US$, Mn), 2017-2028
Figure 37. Bristol-Myers Squibb Malignant Melanoma Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Enzon Pharmaceuticals Malignant Melanoma Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Exelixis Malignant Melanoma Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. GlaxoSmithKline Malignant Melanoma Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Merck Malignant Melanoma Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Pfizer Malignant Melanoma Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Janssen Biotech Malignant Melanoma Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Hoffmann-La Roche Ltd Malignant Melanoma Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Navidea Biopharmaceuticals Malignant Melanoma Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Novartis Malignant Melanoma Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Ono Pharmaceutical Malignant Melanoma Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Amgen Malignant Melanoma Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)

Report Title: Malignant Melanoma Drugs Market - Global Outlook and Forecast 2022-2028


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW